Treatment of psychosis in Parkinson;Tratamiento de la psicosis Parkinsoniana

Revista de Neurologia

Volumn 48, Issue 12, 2009, Pages 645-653

  Durán Ferreras, Eduardo ^a,c   Chacon J R ^b  

^a HOSPITAL INFANTA ELENA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c NONE   (Spain)

Author keywords

Atypical antipsychotics; Hallucinations; Parkinson's disease; Psychosis; Treatment

Indexed keywords

AMANTADINE; AMISULPRIDE; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABIDIOL; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; HALOPERIDOL; LEVODOPA; MEMANTINE; MONOAMINE OXIDASE B INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PIMAVANSERIN; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN 2A AGONIST; SEROTONIN 3 ANTAGONIST; UNINDEXED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; ALZHEIMER DISEASE; CLINICAL FEATURE; DEGENERATIVE DISEASE; DELUSION; DEMENTIA; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; HUNTINGTON CHOREA; INSTITUTIONALIZATION; LEUKOPENIA; MENTAL DISEASE; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NEUTROPENIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; UNIFIED PARKINSON DISEASE RATING SCALE;

HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS;

EID: 68949204928     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4812.2008573     Document Type: Review

References (124)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely & Jones; 1817.
2. Van den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-1022 (Pubitemid 36628805)
3. Factor S, Weiner W. Parkinson's disease. Diagnosis and clinical management. New York: Demos; 2002.
4. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996-1002.
5. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004; 52: 784-788 (Pubitemid 38596500)
6. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-413 (Pubitemid 34857934)
7. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17: 60-67
8. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-199 (Pubitemid 40361122)
9. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8: 193-197
10. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63: 293-300. (Pubitemid 38971129)
11. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22: 1061-1068 (Pubitemid 47067214)
12. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al, Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872
13. Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 2008; 23: 484-500.
14. Poewe W. When a Parkinson's disease patient starts to hallucinate. Pract Neurol 2008; 8: 238-241
15. Kulisevsky J, Martínez-Ramírez S. Tratamiento de la psicosis en la enfermedad de Parkinson. Neurol Supl 2007; 3: 21-26
16. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 734-738 (Pubitemid 32554202)
17. Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998; 50: 515-517
18. Fénelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson's disease in the prelevodopa era. Neurology 2006; 66: 93-98 (Pubitemid 43739599)
19. Henderson MJ, Mellers JDC. Psychosis in Parkinson's disease: 'between a rock and a hard place'. Int Rev Psychiatry 2000; 12: 319-334
20. Fénelon G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 2008; 13 (Suppl 4): S18-25.
21. Wolters EC. PD-related psychosis: pathophysiology with therapeutical strategies. J Neural Transm Suppl 2006; 71: 31-37
22. Aarsland D, Brønnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42. (Pubitemid 46048261)
23. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001; 16: 528-536 (Pubitemid 32492388)
24. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391-403.
25. Williams DR, Warren JD, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. J Neurol Neurosurg Psychiatry 2008; 79: 652-655
26. Bosboom JL, Wolters EC. Psychotic symptoms in Parkinson's disease: pathophysiology and management. Expert Opin Drug Saf 2004; 3: 209-220 (Pubitemid 38765203)
27. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-745 (Pubitemid 30162723)
28. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605-610
29. Ramírez-Ruiz B, Junqué C, Martí MJ, Valldeoriola F, Tolosa E. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov Disord 2006; 21: 1483-1487 (Pubitemid 44613306)
30. Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in nondemented Parkinsonian patients. Int J Geriatr Psychiatry 2005; 20: 668-673 (Pubitemid 41131778)
31. Barnes J, Boubert L. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. J Neurol Neurosurg Psychiatry 2008; 79: 190-192 (Pubitemid 351236553)
32. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of levodopa psychosis. Clin Neuropharmacol 1982; 5: 183-194
33. Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 2005; 64: 81-86 (Pubitemid 40082941)
34. Marsh L. Psychosis in Parkinson's disease. Primary Psychiatry 2005; 12: 56-62.
35. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 2002; 59: 1249-1252 (Pubitemid 34856377)
36. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998; 21: 289-295 (Pubitemid 28491429)
37. Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996; 347: 794-797 (Pubitemid 26092208)
38. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669-671
39. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866-874 (Pubitemid 29495548)
40. Zahodne LB, Fernández HH. Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? CNS Spectr 2008; 13 (Suppl 4): S26-33.
41. Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry 2007; 164: 1491-1498 (Pubitemid 350069725)
42. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 2008; 79: 652-655
43. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 2005; 13: 844-851
44. Mosimann UP, Rowan EN, Partington CE, Collerton D, Littlewood E, O'Brien JT, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry 2006; 14: 153-160 (Pubitemid 43227638)
45. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 533-535
46. Fénelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson's disease. J Neurol 2002; 249: 1699-1703
47. Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's disease. Parkinsonism Relat Disord 2004; 10: 253-254 (Pubitemid 38534620)
48. Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord 2006; 21: 267-270
49. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56 (Suppl 5): S1-88.
50. Barbas NR. Cognitive, affective, and psychiatric features of Parkinson's disease. Clin Geriatr Med 2006; 22: 773-796 (Pubitemid 44416144)
51. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201-211 (Pubitemid 30167909)
52. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. JAMA 1985; 254: 2792-2795
53. Campbell M, Young PI, Bateman DN, Smith JM, Thomas SHL. The use of atypical antipsychotics in the management of schizophrenia. Br J Clin Pharmacol 1999; 47: 13-22. (Pubitemid 29043159)
54. Lieberman A. Managing the neuropsychiatric symptoms of Parkinson's disease. Neurology 1998; 50 (Suppl 6): S33-8. (Pubitemid 28270378)
55. Collaborative Working Group on Clinical Trial Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998; 59 (Suppl 12): S23-7.
56. Marras C, Kopp A, Qiu F, Lang AE, Sykora K, Shulman KI, et al. Antipsychotic use in older adults with Parkinson's disease. Mov Disord 2007; 22: 319-323 (Pubitemid 46569683)
57. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; in press.
58. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995; 45: 432-434
59. Fernández HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004; 19: 831-833 (Pubitemid 39139598)
60. Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003; 26: 8-11. (Pubitemid 36184109)
61. Pollak P, Tison F, Rascol O, Destée A, Péré JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75: 689-695 (Pubitemid 38526677)
62. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757-763
63. Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol 2007; 17: 165-171 (Pubitemid 44779199)
64. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 9 (Suppl 3): S3-7. (Pubitemid 28196363)
65. Drugs for Parkinson's disease. Treat Guidel Med Lett 2007; 5: 89-94.
66. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and ris peridone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000; 12: 364-369 (Pubitemid 30665218)
67. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994; 344: 681.
68. Rich S, Friedman JH, Ott B. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akynetic-rygid syndromes. J Clin Psychiatr 1995; 56: 556-559 (Pubitemid 26001766)
69. Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000; 15: 1230-7.
70. Workman RH Jr, Orengo CA, Bakey AA, Molinari VA, Kunik ME. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997; 9: 594-597 (Pubitemid 28029756)
71. Rustembegovic A, Sofic E, Wichart I. Serum prolactin, leptin, lipids and lipoprotein levels during antipsychotic treatment in Parkinson's disease and related psychosis. Med Arh 2006; 60: 211-212
72. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1085-1087 (Pubitemid 26362056)
73. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55: 789-794 (Pubitemid 30727717)
74. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52: 438-445 (Pubitemid 35266735)
75. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17: 1031-1035
76. Durán-Ferreras E, Chacón JR, Durán-Quintana JA. Papel de la olanzapina en la psicosis dopaminérgica parkinsoniana. Rev Neurol 2002; 35: 691-696
77. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004; 19: 29-35. (Pubitemid 38559617)
78. Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol 2006; 29: 215-219 (Pubitemid 44510458)
79. Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol 2006; 253: 171-175 (Pubitemid 43255886)
80. Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29: 331-337 (Pubitemid 44729944)
81. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27: 153-156 (Pubitemid 39121725)
82. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months duration. Mov Disord 2007; 22: 313-318 (Pubitemid 46569682)
83. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20: 958-963 (Pubitemid 41419510)
84. Saft C, Andrich J, Kraus PH, Przuntek H. Amisulpride in Huntington's disease. Psychiatr Prax 2005; 32: 363-366
85. Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006; 21: 2078-2081 (Pubitemid 46140415)
86. Fernández HH, Trieschmann ME, Friedman JH. Aripiprazole for drug induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004; 27: 4-5. (Pubitemid 38280379)
87. Schonfeldt-Lecuona C, Connemann BJ. Aripiprazole and Parkinson's Disease Psychosis. Am J Psychiatry 2004; 161: 373-374
88. Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006; 21: 1538-1539 (Pubitemid 44613323)
89. Durán-Ferreras E, Álvarez-López M, García-Moreno JM, Chacón JR. Ziprasidona en la psicosis dopaminérgica parkinsoniana. Rev Neurol 2008; 46: 476-480
90. Gómez-Esteban JC, Zarranz JJ, Velasco F, Lezcano E, Lachen MC, Rouco I, et al. Use of zyprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005; 28: 111-114 (Pubitemid 40923408)
91. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
92. Stübner S, Grohmann R, Engel R, Bandelow B, Ludwig WD, Wagner G, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37 (Suppl 1): S70-8. (Pubitemid 38658333)
93. Cowan C, Oakley C. Leukopenia and neutropenia induced by quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 292-294
94. Montgomery J. Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia. Gen Hosp Psychiatry 2006; 28: 83-85 (Pubitemid 41827576)
95. Pessina A, Turlizzi E, Bonomi A, Guizzardi F, Cavicchini L, Croera C, et al. In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry 2006; 39: 20-22
96. No authors listed. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease. Prescrire Int 2007; 16: 197-198
97. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 324-325
98. Sobow T. Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol Neurochir Pol 2007; 41: 276-279 (Pubitemid 47091107)
99. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25: 107-110 (Pubitemid 34411830)
100. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. D-nepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23: 41-43 (Pubitemid 34591417)
101. Kurita A, Ochiai Y, Kono Y, Suzuki M, Inoue K. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003; 16: 184-188 (Pubitemid 37409030)
102. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171-1174
103. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18: 937-941 (Pubitemid 37294855)
104. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-939 (Pubitemid 40909549)
105. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-712 (Pubitemid 34557010)
106. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19: 1-8. (Pubitemid 38180686)
107. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518 (Pubitemid 39603164)
108. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899-1907 (Pubitemid 44848936)
109. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized controlled studies. Int J Geriatr Psychiatry 2005; 2: 459-464 (Pubitemid 40716339)
110. Cummings JL, Schneider E, Tariot PN, Graham SM and the Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006; 67: 57-63.
111. Sleeper RB. Antipsychotic dose-sparing effect with addition of memantine. Ann Pharmacother 2005; 39: 1573-1576
112. Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65: 481-482 (Pubitemid 41099820)
113. Monastero R, Camarda C, Pipia C, Camarda R. Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry 2007; 78: 546. (Pubitemid 46662914)
114. Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341: 562-563 (Pubitemid 23066122)
115. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45: 1305-1308
116. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopainduced psychosis. Neurology 1996; 47: 1608-1609
117. Abbas A, Roth BL. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008; 9: 3251-3259
118. Pazos A. Acciones de los fármacos. Interacciones fármaco y receptor. In Flórez J, Armijo JA, Mediavilla A, eds. Farmacología humana. 5 ed. Barcelona: Elsevier Masson; 2008. p. 10-14
119. Zuardi A, Crippa J, Hallak J, Pinto J, Chagas M, Rodrigues G, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2008; Nov 21. [Epub ahead of print].
120. Coelho M, Ferreiro J, Rosa M, Sampaio C. Treatment options for non motor symptom in late stage Parkinson's disease. Expert Opin Pharmacother 2008; 9: 523-535
121. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The Expert Consensus Guideline Series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003; 64 (Suppl 12): S2-97.
122. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984; 15: 415-418 (Pubitemid 14145565)
123. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245
124. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 2006; 5: 845-854 (Pubitemid 44480538)